Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Immunic Inc (NASDAQ: IMUX) closed at $0.62 down -5.26% from its previous closing price of $0.66. In other words, the price has decreased by -$5.26 from its previous closing price. On the day, 1.71 million shares were traded. IMUX stock price reached its highest trading level at $0.6703 during the session, while it also had its lowest trading level at $0.62.
Ratios:
For a deeper understanding of Immunic Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on November 07, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
On September 29, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 13 ’25 when Nash Duane bought 20,000 shares for $0.83 per share. The transaction valued at 16,694 led to the insider holds 36,032 shares of the business.
Tardio Jason bought 12,512 shares of IMUX for $9,884 on Jun 05 ’25. The President and COO now owns 12,512 shares after completing the transaction at $0.79 per share. On Jun 04 ’25, another insider, Vitt Daniel, who serves as the CEO and Director of the company, bought 15,000 shares for $0.77 each. As a result, the insider paid 11,550 and bolstered with 29,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMUX now has a Market Capitalization of 74756952 and an Enterprise Value of 40416956.
Stock Price History:
The Beta on a monthly basis for IMUX is 1.53, which has changed by -0.40900898 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, IMUX has reached a high of $1.39, while it has fallen to a 52-week low of $0.56. The 50-Day Moving Average of the stock is -18.52%, while the 200-Day Moving Average is calculated to be -30.52%.
Shares Statistics:
For the past three months, IMUX has traded an average of 1.38M shares per day and 1210370 over the past ten days. A total of 120.28M shares are outstanding, with a floating share count of 118.71M. Insiders hold about 1.31% of the company’s shares, while institutions hold 52.23% stake in the company. Shares short for IMUX as of 1764288000 were 5587275 with a Short Ratio of 4.05, compared to 1761868800 on 8234621. Therefore, it implies a Short% of Shares Outstanding of 5587275 and a Short% of Float of 4.7199998.
Earnings Estimates
A detailed examination of Immunic Inc (IMUX) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.07 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.55 and -$0.76 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.37, with 9.0 analysts recommending between -$0.05 and -$0.67.
